Trial Profile

Bioavailability Study of Intranasal CT001 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ketamine/sufentanil (Primary) ; Ketamine; Sufentanil
Indications Procedural pain
Focus Pharmacokinetics
Sponsors Cessatech

Most Recent Events

23 Aug 2021 Status changed from recruiting to completed.
12 May 2021 Planned primary completion date changed from 1 Jun 2021 to 3 Jun 2021.
24 Mar 2021 According to a Cessatech media release, the paediatric investigation plan (PIP) for CT001 nasal spray has been approved by the European Medicines Agency in November 2019 and this trial is a part of the clinical development plan for treatment of acute pain in children.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com